Precisation prediction of therapeutic response to cancer immunotherapy

Precisation prediction of therapeutic response to cancer immunotherapy Author: Mgr. Jana Novotná Consultant: doc. PharmDr. Josef Malý, Ph.D. Department of Social and Clinical Pharamcy Faculty of Pharmacy in Hradec Králové, Charles University Introduction and aims: Over the last few years, anticancer immunotherapy has increasingly become an important agent in treatment of oncologic patients. The aim of this thesis was to assess the clinical parameters and to find any biological markers that would predict efficacy of pembrolizumab and nivolumab. Methods: The research was based on retrospective data analysis of patients treated with pembrolizumab or nivolumab during 2015-⁠2020 at Oncology Clinic of General Uviersity Hospital in Prague. The patients were divided into responder or non-responder groups based on their treatment response. Subsequently the analysis of clinical parameters, adverse events, panel gene sequencing of tumor DNA and RNA was performed. Finally, the obtained data were tested to find any correlations between biological markers and the treatment outcomes by the descriptive statistic method. Results: The data of 70 patients (60 % men, between 42-⁠86 years old) were analysed. The most frequent patient profile was man in age 70-⁠79 years with non- small cell lung cancer diagnosis. In..